BLASUBCUTANEOUSINJECTABLE
Approved
Feb 2025
Lifecycle
Growth
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
4/8 — Partial
XBRYK (denosumab) by Samsung Bioepis is rank ligand blocking activity [moa]. Approved for osteoporosis, giant cell tumor of bone, breast cancer. First approved in 2025.
Drug data last refreshed 20h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
XBRYK (denosumab) is a monoclonal antibody that blocks RANK ligand, a key driver of bone resorption and tumor progression. It is indicated for osteoporosis, giant cell tumor of bone, and breast cancer. The drug works by inhibiting osteoclast activation and survival, reducing bone loss and tumor-related bone complications.
Growth
Newly approved biosimilar entering a mature RANK ligand market; smaller team scaling to challenge Amgen's PROLIA dominance with cost advantage.
Mechanism of Action
RANK Ligand Blocking Activity
Pharmacologic Class:
RANK Ligand Inhibitor
Indications (3)
Worked on XBRYK at Samsung Bioepis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.